Fenway Park reopens not for Red Sox games but as COVID vaccination site
Updated Jan 30, 2021;
Facebook Share
At the iconic park that is evocative of Boston and Massachusetts, the first two days of vaccinations have been underway. Fenway Park, home of the Red Sox, will now house the vaccination of thousands of fans against the deadly COVID virus.
On Friday, roughly 150 people were vaccinated at the renowned baseball stadium in Boston. This number will increase as the weeks go on and the organizers of the Pfizer-BioNTech vaccinations are able to become more experienced in the distribution.
Site operator, CIC Health has contracted Beth Israel Deaconess Medical Center (BIDMC) to provide medical oversight for the vaccine distribution. CIC Health is also operating the mass vaccination site Gillette Stadium, the first large-scale vaccination facility in Massachusetts which will ramp up to 5,000 vaccinations per day as more supplies become available.
Much has changed for the better since the peak of the HIV/AIDS epidemic in the mid-1980s. The number of new annual HIV infections is less than one-third of what it was. In addition, more HIV-prevention drugs are reaching the marketplace and giving consumers options beyond Truvada, which was approved by the Food and Drug Administration in 2012 and is close to 99% effective when taken daily, as prescribed.
PrEP is a HIV-prevention strategy, which requires a HIV-negative person to take medication. It is “one of the most important tools we have to end the HIV epidemic in the U.S. and around the globe,” says Dr. Douglas Krakower, an infectious disease specialist at Boston’s Beth Israel Deaconess Medical Center. An acronym for pre-exposure prophylaxis, “PrEP is highly effective. It’s very safe in the vast majority of people who use it.”
Close icon
Two crossed lines that form an X . It indicates a way to close an interaction, or dismiss a notification. A clinical-trial volunteer participating in Johnson & Johnson s study to test a coronavirus vaccine. Janssen
A Johnson & Johnson vaccine was found safe with 66% efficacy at preventing COVID-19.
J&J expects to submit the late-stage trial data to the FDA in early February for authorization.
If the vaccine gets the green light, it would boost supplies for the US vaccination campaign.
The US s effort to halt the coronavirus got some good news Friday as another vaccine succeeded in the final stages of clinical research.
First published on
A single shot of a coronavirus vaccine developed by Johnson & Johnson protected volunteers enrolled in a sprawling, multicountry study from developing COVID-19, results disclosed by the company Friday showed.
The finding is a boost to a sputtering global immunization drive, adding another effective vaccine to a mix of shots already cleared for use in dozens of nations. J&J, one of the world s largest drugmakers, expects it can produce 1 billion doses of its vaccine this year.
But the results indicate vaccination was only 66% effective in preventing moderate or severe COVID-19 compared to a saline injection used as placebo. Expectations were for a higher number, particularly after shots developed by Pfizer and Moderna were found to be more than 90% effective at preventing symptomatic COVID-19.
Covid-19: J&J s single-dose coronavirus vaccine 57% effective against SA variant Jan 29, 2021, 03:19 PM
facebook
Janssen
A coronavirus vaccine developed by the healthcare giant Johnson & Johnson is safe and 66% effective at preventing Covid-19, results of a late-stage trial show.
J&J expects to submit the data in early February to the US Food and Drug Administration for emergency use authorization.
If the vaccines get the green light from regulators, it would boost supplies for the US vaccination campaign.
The US effort to halt the coronavirus got some good news on Friday as another vaccine succeeded in the final stages of clinical research.